Pazopanib 200 mg Tablet Exporter | Vision Pharma – Global Pharmaceutical Supplier
Pazopanib 200 mg Tablet
Pazopanib 200 mg Tablet is a prescription medicine containing pazopanib, a targeted anticancer medicine belonging to the tyrosine kinase inhibitor (TKI) class. It works by interfering with specific signaling pathways involved in the growth of blood vessels that can support tumor growth.
Pazopanib is used under specialist medical supervision for certain types of cancer. The appropriate dose, duration, and suitability depend on the patient's medical condition and the prescribing oncologist's assessment.
Product Overview
Product Name: Pazopanib 200 mg Tablet
Active Ingredient: Pazopanib
Strength: 200 mg
Dosage Form: Tablet
Therapeutic Category: Antineoplastic / Tyrosine Kinase Inhibitor
Prescription Status: Prescription medicine
Primary Use: Treatment of certain cancers under specialist supervision
Pazopanib should only be used according to a qualified healthcare professional's prescription and instructions. Patients should not change the dose or discontinue treatment without consulting their healthcare provider.
How Pazopanib Works
Pazopanib inhibits several tyrosine kinases involved in cellular signaling and blood-vessel formation. By blocking these pathways, it can help slow the growth and spread of certain tumors.
The medicine has specific safety considerations and may interact with other medicines. Medical supervision is therefore important throughout treatment.
Important Safety Information
Pazopanib can cause significant adverse effects and requires appropriate medical monitoring. Possible adverse effects include high blood pressure, changes in liver function, diarrhea, nausea, fatigue, and changes in laboratory values.
Patients should inform their healthcare professional about existing medical conditions and all medicines or supplements they are taking before starting treatment.
International Pharmaceutical Markets
Pazopanib is a specialized oncology medicine and is subject to prescription, regulatory, importation, and distribution requirements that vary between countries.
International pharmaceutical markets where oncology medicines may be subject to specific regulatory requirements include:
United States: New York, Los Angeles, Chicago, Houston
United Kingdom: London, Manchester, Birmingham, Glasgow
Canada: Toronto, Vancouver, Montreal, Calgary
Australia: Sydney, Melbourne, Brisbane, Perth
United Arab Emirates: Dubai, Abu Dhabi, Sharjah
South Africa: Johannesburg, Cape Town, Durban
Singapore: Singapore
Malaysia: Kuala Lumpur, George Town
Philippines: Manila, Cebu City
Kenya: Nairobi, Mombasa
Nigeria: Lagos, Abuja
Availability and lawful supply of prescription oncology medicines differ by jurisdiction. Appropriate authorization and compliance with local pharmaceutical regulations are essential.
Frequently Asked Questions
Q1. What is Pazopanib 200 mg Tablet?
Pazopanib 200 mg Tablet is a prescription tyrosine kinase inhibitor used for certain types of cancer.
Q2. What is the active ingredient in Pazopanib 200 mg Tablet?
The active ingredient is pazopanib.
Q3. What therapeutic category does pazopanib belong to?
Pazopanib belongs to the antineoplastic and tyrosine kinase inhibitor categories.
Q4. Is Pazopanib 200 mg Tablet a prescription medicine?
Yes. Pazopanib is a prescription oncology medicine and should be used under qualified medical supervision.
Q5. Can the dosage be changed without medical advice?
No. Dose adjustments should only be made by the treating healthcare professional.
Q6. Does pazopanib require medical monitoring?
Yes. Treatment may require monitoring such as blood pressure assessment and liver-function testing, depending on the patient's circumstances and the prescribing clinician's instructions.
Pazopanib 200 mg Tablet, pazopanib tablets, pazopanib active ingredient, tyrosine kinase inhibitor, oncology medicines, anticancer therapy, targeted cancer treatment, pharmaceutical oncology products, prescription cancer medicine, oncology treatment information, VEGF pathway inhibitor.
